Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

Net of cash, the company's enterprise value is around $30m, which is lower than it was under Tom Moore's tenure when the company wasn't in Phase 3 and didn't have any BP collaborations. Goes to show how O'Connor's wasteful spending, unethical self-dealing and lavish non-performance based comp policies, crappy deals and no real business strategy destroyed significant value even though the company advanced clinically. But hey, while the company's owners/investors may have been screwed, at least employees voted it the best place to work on NJ.